New Rochelle, NY, April 7, 2011--A growing body of research suggests that caffeine disrupts glucose metabolism and may contribute to the development and poor control of type 2 diabetes, a major public health problem. A review article in the inaugural issue of Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a quarterly peer-reviewed journal from Mary Ann Liebert, Inc. publishers, examines the latest evidence, contradicting earlier studies suggesting a protective effect of caffeine. The entire issue is available free online.
James Lane, PhD, Duke University, describes numerous studies that have demonstrated caffeine's potential for increasing insulin resistance (impaired glucose tolerance) in adults that do not have diabetes, an effect that could make susceptible individuals more likely to develop the disease. In adults with type 2 diabetes, studies have shown that the increase in blood glucose levels that occurs after they eat carbohydrates is exaggerated if they also consume a caffeinated beverage such as coffee. This effect could contribute to higher glucose levels in people with diabetes and could compromise treatment aimed at controlling their blood glucose.
"More than 220 million people worldwide have diabetes, says Editor-in-Chief Jack E. James, PhD, School of Psychology, National University of Ireland, Galway, Ireland. "The links that have been revealed between diabetes and the consumption of caffeine beverages (especially coffee) are of monumental importance when it is acknowledged that more than 80% of the world's population consumes caffeine daily. Dr. Lane's review of the topic gives the clearest account to date of what we know, what we don't know, and what needs to be done - urgently!"
Journal of Caffeine Research provides a much-needed authoritative source and central forum to advance knowledge of caffeine science and caffeine's effects on human health. It strives to be inclusive with respect to the diversity of research methodologies used to investigate caffeine, and the diversity of views and opinions regarding its mechanisms and effects, and will combine scientific research and clinical studies on caffeine, with an impact across many fields.
The inaugural issue of the Journal captures the broad scope of debate and research in this emerging clinical and scientific arena. Included are an interview on "Caffeine Consumption and Combat Stress amongst Military Personnel," a provocative roundtable discussion on "Caffeine, Alcohol, and Youth: A Toxic Mix," and articles on "Effects of Caffeine Consumption by Women and Men on the Outcome of In Vitro Fertilization," "The 'Buzz' on Caffeine: Patterns of Caffeine Use in a Convenience Sample of College Students," "Gender Differences in Subjective and Physiological Responses to Caffeine and the Role of Steroid Hormones," "Loss of Coronary Dilation to N6-2-(4-Aminophenyl) Ethyladenosine in Isolated Hearts from Chronic Caffeine- and Nifedipine-Treated Rats," "Energy Drink Use and Substance Use among Musicians," and more.
Journal of Caffeine Research publishes original articles, review articles, and editorials, an Experts Speak opinion column focusing on urgent research priorities, informative interviews with experts in the field, roundtable discussions on emerging and controversial topics, and a Literature Watch that presents the breadth and scope of papers recently published in the field. The Journal covers possible effects of caffeine on a wide range of diseases and conditions, including mood disorders, neurological disorders, cognitive performance, cardiovascular disease, and sports performance. The Journal will explore all aspects of caffeine science including the biochemistry of caffeine; its actions on the human body; benefits, dangers, and contraindications; and caffeine addiction and withdrawal, across all stages of the human life span from prenatal exposure to end-of-life.
The Journal editorial leadership includes Editor-in-Chief Jack E. James, PhD and a distinguished multidisciplinary editorial board including Roland Griffiths, PhD, Johns Hopkins School of Medicine; James Lane, PhD, Duke University Medical School; Sergi Ferre, MD, PhD, National Institute on Drug Abuse, and Mary Claire O'Brien, MD, Wake Forest University School of Medicine, and other leading investigators. To view the entire editorial board, please visit our website.
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Medicinal Food, Journal of Neurotrauma, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available on our website.